IMMORTALIZED CAR-T CELLS GENETICALLY MODIFIED TO ELIMINATE T-CELL RECEPTOR AND BETA 2-MICROGLOBULIN EXPRESSION - Patent 3724321

(19)

(11)

EP 3 724 321 A1

(12)

(43)	Date of publication:
	21.10.2020 Bulletin 2020/43

(21)	Application number: 18888643.6

(22)	Date of filing: 11.12.2018

(51)

International Patent Classification (IPC):

C12N 5/0783^(2010.01)
C07K 14/725^(2006.01)
A61K 35/17^(2015.01)

C07K 16/28^(2006.01)
C07K 14/74^(2006.01)
A61P 35/00^(2006.01)

(86)	International application number:
	PCT/US2018/064971

(87)	International publication number:
	WO 2019/118475 (20.06.2019 Gazette 2019/25)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME
	Designated Validation States:
	KH MA MD TN

(30)

Priority:

13.12.2017 US 201762598032 P

(71)	Applicant: Janssen Biotech, Inc.
	Horsham, PA 19044 (US)

(72)	Inventors:
	LEE, John Spring House, PA 19477 (US) MOONEY, Jill San Diego, CA 92117 (US) NASO, Michael Swarthmore, PA 19081 (US)

(74)	Representative: Gill Jennings & Every LLP
	The Broadgate Tower 20 Primrose Street London EC2A 2ES London EC2A 2ES (GB)

(54)	IMMORTALIZED CAR-T CELLS GENETICALLY MODIFIED TO ELIMINATE T-CELL RECEPTOR AND BETA 2-MICROGLOBULIN EXPRESSION